Navigation Links
Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference

0 new patients are infected each year. It is estimated that 10,000 to 12,000 patients die annually in the United States from complications resulting from HCV infection. The current standard of care for treating chronic hepatitis C is combination therapy consisting of pegylated alpha interferon and ribavirin.

About Diabetes

Diabetes affects more than 20 million in the United States and an estimated 194 million adults worldwide. Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the United States. According to the U.S. Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve target A1c levels with their current treatment regimen.

DUROS is a registered trademark of ALZA Corporation (Mountain View, CA) licensed to Intarcia Therapeutics, Inc. Intarcia and its logo are trademarks of Intarcia Therapeutics, Inc. (Emeryville, CA).

CONTACT: James Ahlers, Chief Financial Officer of Intarcia Therapeutics,+1-510-652-2600, ext 235

Web site: http://www.intarcia.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:11/22/2014)... , Nov. 22, 2014  Sprout Pharmaceuticals today announced ... demonstrate that women treated with flibanserin up to 200 mg ... data were presented at the 20 th Annual Fall ... North America in Miami . ... response to the Complete Response Letter and the Formal Dispute ...
(Date:11/22/2014)... , Nov. 22, 2014  New data demonstrates ... the most common form of female sexual dysfunction, Hypoactive ... function or driving performance in premenopausal women when taken ... Medicine Society of North America,s ... Miami . SMSNA accepted this ...
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
Breaking Medicine Technology:Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... 16 , - Promising Efficacy ... Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) ... II studies evaluating,the efficacy, safety and tolerability of QVA149 at ... QVA149 is a novel once-daily,dry powder fixed dose bronchodilator combination ...
... , , ... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today ... rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from ... 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ...
Cached Medicine Technology:QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 2QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 3QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 2Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 3Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 5Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 6
(Date:11/23/2014)... To show thanks to new and old customers, ... white evening dresses for weddings. Customers who need custom ... is a distinguished dress manufacturer, and it is among the ... for a very long time. The CEO of this company ... be able to buy not only a beautiful dress, but ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers ... has announced its new collection of power suppliers. Additionally, ... quality power suppliers. All the new models come with ... lasts until Dec. 20, 2014. , SWAccessControl.com has thousands ... supporting it for a long time. It is very ...
(Date:11/23/2014)... More than two dozen new claims were ... involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), as well as ... , A Case List updated on November 17th ... 2 diabetes medications referred to as incretin mimetics have ... District of California, where a federal proceeding continues to ...
(Date:11/23/2014)... AngelWeddingDress.com has recently updated ... of beach wedding dresses. “If you are looking for ... as soon as possible. Here you can enjoy 70% ... says. , Holding a big marriage ceremony is the ... beautiful beach wedding dress is uppermost priority. Ophelia, one ...
(Date:11/23/2014)... CA (PRWEB) November 23, 2014 ... American Medical Aesthetics & Wellness was recently featured ... Milgrom, Ph.D. is president and CEO of American Medical ... Dr. Asher Milgrom received a full scholarship to attend ... the Medical School at the University of Chicago, where ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4
... Development, and Health at Harvard School of Public Health, has ... found that the disease costs a person $3.2 million over ... the new book Understanding Autism: From Basic Neuroscience to Treatment ... Autism,” Ganz says that autism costs $35 billion per year ...
... open a second cancer hospital, this time in the southern ... up in Karachi by January next year, the Daily Times ... had set up the Shaukat Khanum Memorial Cancer Hospital and ... state-of-the-art cancer centre was Khan's tribute to his mother Shaukat ...
... of the Irish Medical Organization (IMO) has expressed his interest ... . Previously, Nora Owen, the party’s former Justice Minister held ... nomination in the Dublin North constituency and is positive about ... held on the 2nd of May. ,‘The people ...
... flu in ducks on Indonesia's resort island of Bali, health ... of bird flu// . The birds had been smuggled to ... Putra, senior government veterinarian. ,More than 24 bird ... most populous nation. In response to the above situation, import ...
... Researchers from the Simon Bolivar University in Caracas found ... the beans reduced its flatulence capacity// and increased the ... of nutrition especially in the developing countries. ... method of creating flatulence-free beans but not compromising on ...
... University suggests that men are more aware of potential rivals ... The researchers felt that men// become more jealous and wary ... their most fertile. ,The Evolution and Human Behaviour ... with ovulating partners were vary wary of the dominant looking ...
Cached Medicine News:Health News:The Price Of Autism 2Health News:Jealousy In Men Peaks When Partners Are Most Fertile 2
... Millbrook Practice Manager® is now known ... (PM). Centricity Physician Office - PM is ... and structure, providing an easily adaptable solution ... physician offices of every specialty and ...
... practice management systems have brought cutting-edge software ... in the world. Today, Intuition PM delivers ... a friendly, intuitive manner. Automate patient registration ... in-office patient processing through wireless hand-held PC's, ...
... Electronic Medical Records module is designed ... costs and increase revenues. It creates ... minimal effort while it streamlines workflow, ... related to patient care outcomes. NextGen ...
... Intuition EMR family of products offers ... range of specialties. Intuition EMR enables ... full electronic record at the point ... spend less time on documentation and ...
Medicine Products: